ace1831
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2022 (NCT05653271)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07061938 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2025 | Acepodia Biotech Inc. |
| NCT05653271 | Phase 1 | Dec 31, 2022 | Acepodia Biotech Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Acepodia Biotech Inc. | For profit | 2 | 2 | 2 | 2022 |
1 organizations
Page 1 / 1